Tags

Type your tag names separated by a space and hit enter

Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
Dermatol Ther. 2016 Sep; 29(5):358-363.DT

Abstract

Cutaneous leishmaniasis (CL) treatment is based on pentavalant antimony (sbv) drugs which are accompanied by many side effects and are facing ever-increasing resistance. Topical treatment of CL is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. The liposomal formulations of different drugs have recently been increasingly used in the treatment of several types of leishmaniasis. The efficacy of a topical liposomal azithromycin formulation was compared with intralesional meglumine antimoniate (glucantime) in the treatment of CL. Sixty-six patients with 97 lesions who met our inclusion criteria were randomly divided into two groups. One group was administered with the topical liposomal form of azithromycin twice daily. The other group was treated by weekly intralesional injections of glucantime with a volume of 0.5-2 cm3 into each lesion till complete blanching of the lesion occurred. Clinical evaluations were performed weekly during the treatment course (8 weeks) by a single dermatologist for both groups. Per-protocol analysis showed no statistically significant difference between the two groups (p = 0.84, 95% confidence interval (CI) = 0.764 (0.714-0.821). Serious drug side effects were not observed in either group. Topical liposomal azithromycin has the same efficacy as intralesional glucantime in the treatment of CL.

Authors+Show Affiliations

Department of Drug and Food Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Cutaneous Leishmaniasis Research Center, Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran. layeghpo@mums.ac.ir.Cutaneous Leishmaniasis Research Center, Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27073044

Citation

Rajabi, Omid, et al. "Topical Liposomal Azithromycin in the Treatment of Acute Cutaneous Leishmaniasis." Dermatologic Therapy, vol. 29, no. 5, 2016, pp. 358-363.
Rajabi O, Layegh P, Hashemzadeh S, et al. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis. Dermatol Ther. 2016;29(5):358-363.
Rajabi, O., Layegh, P., Hashemzadeh, S., & Khoddami, M. (2016). Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis. Dermatologic Therapy, 29(5), 358-363. https://doi.org/10.1111/dth.12357
Rajabi O, et al. Topical Liposomal Azithromycin in the Treatment of Acute Cutaneous Leishmaniasis. Dermatol Ther. 2016;29(5):358-363. PubMed PMID: 27073044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis. AU - Rajabi,Omid, AU - Layegh,Pouran, AU - Hashemzadeh,Sara, AU - Khoddami,Mohsen, Y1 - 2016/04/12/ PY - 2016/4/14/pubmed PY - 2017/3/21/medline PY - 2016/4/14/entrez KW - azithromycin KW - cutaneous leishmaniasis KW - liposome KW - treatment SP - 358 EP - 363 JF - Dermatologic therapy JO - Dermatol Ther VL - 29 IS - 5 N2 - Cutaneous leishmaniasis (CL) treatment is based on pentavalant antimony (sbv) drugs which are accompanied by many side effects and are facing ever-increasing resistance. Topical treatment of CL is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. The liposomal formulations of different drugs have recently been increasingly used in the treatment of several types of leishmaniasis. The efficacy of a topical liposomal azithromycin formulation was compared with intralesional meglumine antimoniate (glucantime) in the treatment of CL. Sixty-six patients with 97 lesions who met our inclusion criteria were randomly divided into two groups. One group was administered with the topical liposomal form of azithromycin twice daily. The other group was treated by weekly intralesional injections of glucantime with a volume of 0.5-2 cm3 into each lesion till complete blanching of the lesion occurred. Clinical evaluations were performed weekly during the treatment course (8 weeks) by a single dermatologist for both groups. Per-protocol analysis showed no statistically significant difference between the two groups (p = 0.84, 95% confidence interval (CI) = 0.764 (0.714-0.821). Serious drug side effects were not observed in either group. Topical liposomal azithromycin has the same efficacy as intralesional glucantime in the treatment of CL. SN - 1529-8019 UR - https://www.unboundmedicine.com/medline/citation/27073044/Topical_liposomal_azithromycin_in_the_treatment_of_acute_cutaneous_leishmaniasis_ DB - PRIME DP - Unbound Medicine ER -